Hikma Pharma GmbH enters into an exclusive co-promotion agreement with Therabel Pharma Deutschland GmbH

Munich (ots) - Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai:
HIK) ("Hikma"), the fast growing multinational pharmaceutical group,
today announces that Hikma Pharma GmbH, a wholly-owned subsidiary,
has entered into an exclusive co-promotion agreement with Therabel
Pharma Deutschland GmbH to support the launch of Loramyc® for cancer
patients in the retail oncology community. Commenting on the
agreement, Dr. Martin Stapf, General Manager Germany and Global
Business Unit Director Oncology of Hikma Pharma GmbH said "We are
delighted to be partnering with Therabel, bringing together
Therabel's strong knowledge and broad coverage of the German hospital
market and Hikma Pharma GmbH's extensive experience in the oncology
segment through its ribosepharm division. This combination will
provide the market access required to ensure the success of this
specialty drug in the oncology segment."

Commenting on the partnership, Jean-Michel Robert, President of
the Strategic committee of Therabel said "Our team is committed to
create a hospital presence through Loramyc® with oncologists and HIV
specialists and we are delighted to deepen this presence further with
the experience and support of Hikma sales force directed to private
oncologists and hematologists."

About Loramyc®

Loramyc® is an antifungal drug indicated for the treatment of
oropharyngeal candidiasis in immunocompromised patients, including
those with cancer and HIV. Loramyc®, which received marketing
authorization in France in October 2006, is an antifungal delivered
in a mucoadhesive buccal tablet, enabling an early and extended
release of the active ingredient at the site of infection, with once-
daily dosing. About THERABEL PHARMA Therabel is a privately owned,
medium-size, specialty pharmaceutical company. Its activities are
focused on Western Europe. The company was founded in 1945 and has
since expanded from a strong base in the Benelux countries to operate
in other parts of Europe, notably France (Therabel Lucien Pharma,
Therabel Hôpital Pharma), Italy (Therabel Pharma Italia) and more
recently the UK, through Therabel's acquisition of Javelin
Pharmaceuticals UK Ltd in January 2009 (now Therabel Pharma UK Ltd).
In January 2010, Therabel Pharma Deutschland GmbH was incorporated in
Germany. Therabel turnover in 2009 was E160 million. There are more
than 350 employees, the majority of which comprises the sales force
and sales and marketing management. Therabel does not undertake R&D,
but instead grows the business through its product in-licensing and
acquisition activities. For more information, visit Therabel website
at www.therabel.com .

About Hikma

Hikma Pharmaceuticals PLC is a fast growing multinational
pharmaceutical group focused on developing, manufacturing and
marketing a broad range of both branded and non-branded generic and
in-licensed products. Hikma's operations are conducted through three
businesses: "Branded", "Injectables" and "Generics" based principally
in the Middle East and North Africa ("MENA") region, where it is a
market leader, the United States and Europe. In 2010, Hikma achieved
revenues of $731 million and profit attributable to shareholders of
$99 million.

For more information, visit Hikma website at www.hikma.com .

Contact
Dr. Martin Stapf
General Manager
ribosepharm division
Hikma Pharma GmbH
Lochhamer Schlag 17
82166 Gräfelfing
martin.stapf@hikma.de

Andrea Brüwer
Tel.: +49 (89) 45 45 0-100
Fax: +49 (89) 45 45 0-166
abruewer@hikma.de